Why the study?
Idiopathic recurrent pericarditis is an underestimated disease with shifting treatment paradigms, requiring updated discussion on diagnosis and therapy following recent publications.
This expert position statement outlines updated diagnostic and therapeutic strategies for idiopathic recurrent pericarditis in the Russian Federation.
Answers are grounded in this paper and cite their sources.
Updates management of idiopathic recurrent pericarditis; extends prior guidance to incorporate recent treatment paradigm shifts.
Pericarditis as an inflammatory heart disease is rarely discussed in the cardiology community. The latest European guidelines on pericarditis were published in 2015, and Russian clinical guidelines are dated 2022. However, in recent years, a number of publications have appeared that have forced the scientific community to take a fresh look at this problem. This is mainly due to a change in the paradigm of the treatment of idiopathic recurrent pericarditis (IRP) registered in the Russian Federation as a rare (orphan) disease. According to most experts, IRP is an underestimated cardiac disease, which, due to the lack of specific symptoms and the physicians' alertness regarding the IRP diagnostics, is rarely the subject of scientific discussions. The issues of diagnosis and therapy of IRP in light of the latest reports became the matter under discussion for a group of leading Russian experts chaired by Corresponding Member of the Russian Academy of Sciences, Professor G.P. Arutyunov.
No takes yet. Share an insight, caveat, or question.
Arutyunov et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: